Fondaparinux

Current Pharmaceutical Design

Volumn 11, Issue 4, 2005, Pages 415-419

  Tan, Kiat T ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Acute coronary syndrome; Deep vein thrombosis prophylaxis; Factor X inhibitors; Fondaparinux; Pentassacharide

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PROTAMINE; WARFARIN;

ACUTE DISEASE; ANTICOAGULATION; BLEEDING DISORDER; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LEG; LUNG EMBOLISM; MAJOR SURGERY; NAUSEA; ORTHOPEDIC SURGERY; OSTEOPENIA; PHLEBOGRAPHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; VOMITING;

ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; FACTOR X; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; THROMBOEMBOLISM;

EID: 13444301536     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382089     Document Type: Review

References (22)

1. Tan KT, Lip GY. Red vs White thrombi: Are we treating the right clot? Arch Intern Med 2003; 163: 2534-35.
2. Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
3. Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
4. Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.
5. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.
6. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.
7. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.
8. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-40.
9. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. Circulation 2000; 102: 2726-31.
10. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor Xa inhibitor as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001; 22: 1716-24.
11. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109: 1-11.
12. Boneu B, Necciari J, Carious R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74: 1468-73.
13. van Amsterdam RG, Vogel GM, Visser A, et al. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 1995; 15: 495-503.
14. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
15. Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism, after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003; 362: 504-5.
16. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: 122-130.
17. Eriksson BI, Lassen MR. Duration of Prophylaxis Against Venous Thromboembolism With Fondaparinux After Hip Fracture Surgery. Arch Intern Med 2003; 163: 1337-42.
18. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-8.
19. Elalamy I, Lecrubier C, Potevin F, et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 1995; 74: 1384.
20. Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Design 2004; 10(9): 939-49.
21. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28): 2337-47.
22. Messmore HL, Coyne E, Wehrmacher WH, Demir AM, Fareed J. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Curr Pharm Design 2004; 10(9): 1001-10.